1.Pharmacogenetics of cutaneous flushing response to niacin/ laropiprant combination in Hong Kong Chinese patients with dyslipidemia

Hu, M, Yang, YL, Cha     More...

Hu, M, Yang, YL, Chan, P, Tomlinson, B     Less

PHARMACOGENOMICS[1462-2416], Published 2015, Volume 16, Issue 12, Pages 1387-1397

收錄情况： WOS SCOPUS

WOS核心合集引用: 4  2022影響因子:  2.1  发表年影響因子:  2.710 

2.Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments

To, KKW, Hu, M, Toml     More...

To, KKW, Hu, M, Tomlinson, B     Less

PHARMACOGENOMICS[1462-2416], Published 2014, Volume 15, Issue 8, Pages 1091-1104

收錄情况： WOS SCOPUS

WOS核心合集引用: 11  2022影響因子:  2.1  发表年影響因子:  3.218 

3.Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia

Hu, M, Mak, VWL, Xia     More...

Hu, M, Mak, VWL, Xiao, YJ, Tomlinson, B     Less

PHARMACOGENOMICS[1462-2416], Published 2013, Volume 14, Issue 1, Pages 25-34

收錄情况： WOS SCOPUS

WOS核心合集引用: 17  2022影響因子:  2.1  发表年影響因子:  3.425 

4.Pharmacogenomics of lipid-lowering therapies

Hu, M, Tomlinson, B     More...

Hu, M, Tomlinson, B     Less

PHARMACOGENOMICS[1462-2416], Published 2013, Volume 14, Issue 8, Pages 981-995

收錄情况： WOS SCOPUS

WOS核心合集引用: 21  2022影響因子:  2.1  发表年影響因子:  3.425 

5.Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients

Lee, HK, Hu, M, Lui,     More...

Lee, HK, Hu, M, Lui, SSH, Ho, CS, Wong, CK, Tomlinson, B     Less

PHARMACOGENOMICS[1462-2416], Published 2013, Volume 14, Issue 11, Pages 1283-1294

收錄情况： WOS SCOPUS

WOS核心合集引用: 83  2022影響因子:  2.1  发表年影響因子:  3.425